A5069488409- Immunotherapy and Immune Responses
- CAR-T cell therapy research
- Melanoma and MAPK Pathways
- NF-κB Signaling Pathways
- Cancer Immunotherapy and Biomarkers
- Cancer Cells and Metastasis
- Immune Response and Inflammation
- Single-cell and spatial transcriptomics
- Immune Cell Function and Interaction
- Gene Regulatory Network Analysis
- Cutaneous Melanoma Detection and Management
- Cancer Genomics and Diagnostics
- Protein Degradation and Inhibitors
- Virus-based gene therapy research
- Cytokine Signaling Pathways and Interactions
- Nonmelanoma Skin Cancer Studies
Université Claude Bernard Lyon 1
2021-2025
Centre National de la Recherche Scientifique
2021-2025
Centre Léon Bérard
2022-2025
Inserm
2021-2025
Centre de Recherche en Cancérologie de Lyon
2021-2025
Medical University of Vienna
2025
St. Anna Children's Cancer Research Institute
2024
St Anna Children's Hospital
2024
Cancer Research Center
2022-2023
Background The efficacy of immunotherapies in metastatic melanoma depends on a robust T cell infiltration. Oncogenic alterations tumor cells have been associated to exclusion. Identifying novel cancer cell-intrinsic non-genetic mechanisms immune escape, the targeting which would reinstate recruitment, allow restore response anti-programmed death protein 1 (PD-1) antibody therapy. epithelial-to-mesenchymal transition (EMT)-inducing transcription factor ZEB1 is major regulator plasticity,...
We present a single-arm, phase II, neoadjuvant trial with the oncolytic virus talimogene laherparepvec (T-VEC) in 18 patients difficult-to-resect cutaneous basal cell carcinomas. The primary end point, defined as proportion of patients, who after six cycles T-VEC (13 weeks), become resectable without need for plastic reconstructive surgery, was already achieved stage I (9 patients; 50.0%); thus study discontinued early success. objective response rate 55.6% and complete pathological 33.3%....
Abstract Cell plasticity sustains intra-tumor heterogeneity and treatment resistance in melanoma. Deciphering the transcriptional mechanisms governing reversible phenotypic transitions between proliferative/differentiated invasive/stem-like states is required. Expression of ZEB1 transcription factor frequently activated melanoma, where it fosters adaptive to targeted therapies. Here, we performed a genome-wide characterization targets, by combining ChIP-sequencing RNA-sequencing, upon...
The outcome of cancer and autoimmunity is often dictated by the effector functions CD4+ conventional T cells (Tconv). Although activation NF-κB signaling pathway has long been implicated in Tconv biology, cell-autonomous roles separate transcription-factor subunits are unknown. Here, we dissected contributions canonical RelA c-Rel to function. RelA, rather than c-Rel, regulated cytokine production at steady-state was required for polarization toward TH17 lineage vitro. Accordingly,...
Tumor cells can evade antitumor immune response by expressing the PD-L1 ligand, leading to inhibition of PD-1-expressing T lymphocytes. The mechanisms that regulate expression in cancer are imperfectly characterized. transcription factor ZEB1, a major regulator phenotype switching melanoma cells, was shown promote escape repressing cell infiltration. Using inducible models and ZEB1 gain/loss-of-function melanoma, we show binds CD274 (PD-L1) promoter, directly enhancing mRNA its at membrane....
Abstract Metastatic melanoma patients carrying a BRAF V600 mutation can be treated with combination of and MEK inhibitors (BRAFi/MEKi), but innate acquired resistance invariably occurs. Predicting patient response to targeted therapies is crucial guide clinical decision. We describe here the development highly efficient patient‐derived xenograft model adapted biopsies, using avian embryo as host (AVI‐PDX TM ). In this in vivo paradigm, we depict fast reproducible tumor engraftment samples...
The WHO classification identifies nine classes of melanocytic proliferations according to location, UV exposure, histological, and genetic features. Only a minority lesions remain unclassified. We describe five cases that harbored either an ERBIN-RASGRF2 or ATP2B4-RASGRF2 in-frame fusion transcript. These were collected from different studies, unified only by the lack identifiable known mutations, with highly variable phenotype. One case was large abdominal congenital nevus, three slowly...
Abstract Cell plasticity sustains intra-tumor heterogeneity and treatment resistance in melanoma. Deciphering the transcriptional mechanisms governing reversible phenotypic transitions between proliferative/differentiated invasive/stem-like states is required. Expression of ZEB1 transcription factor frequently activated melanoma, where it fosters adaptive to targeted therapies. Here, we performed a genome-wide characterization targets, by combining ChIP-sequencing RNA-sequencing, upon...
CD8 + T cells are critical mediators of pathogen clearance and anti-tumor immunity. Although signaling pathways leading to the activation NF-κB transcription factors have crucial functions in regulation immune responses, cell-autonomous roles different subunits, still unresolved. Here, we investigated function ubiquitously expressed factor RelA T-cell biology using a novel mouse model gene-edited human cells. We found that cell-specific ablation markedly altered transcriptome ex vivo...
Abstract Metastatic melanoma patients carrying a BRAF V600 mutation can be treated with inhibitors (BRAFi), in combination MEK (MEKi), but innate and acquired resistance invariably occurs. Resistance involve transcriptional- epigenetic-based phenotypic adaptations, as yet unpredictable. Predicting patient response to targeted therapies is crucial guide clinical decision. We describe here the development of highly efficient patient-derived xenograft model adapted biopsies, using avian embryo...